Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Lenihan

Showing results (51-60 of 80) with videos related to

Pageof 8
Sort By:
Blood Advances|July 12, 2018
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trialsAjai Chari, A Keith Stewart, Stuart D Russell, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 27, 2017
Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain AmyloidosisOluchi Oke, Tarsheen Sethi, Stacey Goodman, et al.
Clinical and Translational Science|May 24, 2024
Metabolomic signatures of carfilzomib-related cardiotoxicity in patients with multiple myelomaSamia Shabnaz, Trang N Nguyen, Roy Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2017
Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell CarcinomaVivek Narayan, Stephen Keefe, Naomi Haas, et al.
American Heart Journal|February 7, 2012
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitorsRichard M Steingart, George L Bakris, Helen X Chen, et al.
Frontiers in Cardiovascular Medicine|July 6, 2023
Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myelomaMarwa Tantawy, Guang Yang, Raghunandan Reddy Algubelli, et al.
Circulation|November 11, 2016
Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart AssociationBiykem Bozkurt, Monica Colvin, Jennifer Cook, et al.
Clinical Pharmacology and Therapeutics|February 2, 2026
Causal Effects of Hydrophilic Bile Acids on Carfilzomib-Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization StudySamia Shabnaz, Eric Farber-Eger, Marwa Tantawy, et al.
JACC. Heart Failure|October 28, 2023
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac DysfunctionVennela Avula, Garima Sharma, Mikhail N Kosiborod, et al.
Psychosomatic Medicine|December 4, 2015
Depression and Oropharynx Cancer OutcomeEileen H Shinn, Alan Valentine, Amit Jethanandani, et al.
Pageof 8

Showing results (51-60 of 80) with videos related to

Sort By:
Pageof 8
Blood Advances|July 12, 2018
Analysis of carfilzomib cardiovascular safety profile across relapsed and/or refractory multiple myeloma clinical trialsAjai Chari, A Keith Stewart, Stuart D Russell, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|May 27, 2017
Outcomes from Autologous Hematopoietic Cell Transplantation versus Chemotherapy Alone for the Management of Light Chain AmyloidosisOluchi Oke, Tarsheen Sethi, Stacey Goodman, et al.
Clinical and Translational Science|May 24, 2024
Metabolomic signatures of carfilzomib-related cardiotoxicity in patients with multiple myelomaSamia Shabnaz, Trang N Nguyen, Roy Williams, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 16, 2017
Prospective Evaluation of Sunitinib-Induced Cardiotoxicity in Patients with Metastatic Renal Cell CarcinomaVivek Narayan, Stephen Keefe, Naomi Haas, et al.
American Heart Journal|February 7, 2012
Management of cardiac toxicity in patients receiving vascular endothelial growth factor signaling pathway inhibitorsRichard M Steingart, George L Bakris, Helen X Chen, et al.
Frontiers in Cardiovascular Medicine|July 6, 2023
Whole-Exome sequencing analysis identified TMSB10/TRABD2A locus to be associated with carfilzomib-related cardiotoxicity among patients with multiple myelomaMarwa Tantawy, Guang Yang, Raghunandan Reddy Algubelli, et al.
Circulation|November 11, 2016
Current Diagnostic and Treatment Strategies for Specific Dilated Cardiomyopathies: A Scientific Statement From the American Heart AssociationBiykem Bozkurt, Monica Colvin, Jennifer Cook, et al.
Clinical Pharmacology and Therapeutics|February 2, 2026
Causal Effects of Hydrophilic Bile Acids on Carfilzomib-Related Cardiovascular Events in Multiple Myeloma: A Mendelian Randomization StudySamia Shabnaz, Eric Farber-Eger, Marwa Tantawy, et al.
JACC. Heart Failure|October 28, 2023
SGLT2 Inhibitor Use and Risk of Clinical Events in Patients With Cancer Therapy-Related Cardiac DysfunctionVennela Avula, Garima Sharma, Mikhail N Kosiborod, et al.
Psychosomatic Medicine|December 4, 2015
Depression and Oropharynx Cancer OutcomeEileen H Shinn, Alan Valentine, Amit Jethanandani, et al.
Pageof 8